Potential P-glycoprotein (P-gp) inhibitors from SuperDRUG2 database toward reversing multidrug resistance in cancer treatment: Database mining, molecular dynamics, and binding energy estimations

Funding Sponsor

King Saud University

Author's Department

Chemistry Department

Fourth Author's Department

Chemistry Department

Fifth Author's Department

Chemistry Department

Find in your Library

https://doi.org/10.1016/j.jmgm.2025.108997

All Authors

Khlood A.A. Abdeljawaad Alaa H.M. Abdelrahman Peter A. Sidhom Hatem Tallima Tamer Shoeib Gamal A.H. Mekhemer Shaban R.M. Sayed Mohamed A. El-Tayeb Mohamed Elamir F. Hegazy Mahmoud A.A. Ibrahim

Document Type

Research Article

Publication Title

Journal of Molecular Graphics and Modelling

Publication Date

6-1-2025

doi

10.1016/j.jmgm.2025.108997

Abstract

P-glycoprotein (P-gp) transporter is included in the failure of various carcinoma chemotherapeutics because of the multidrug resistance (MDR) phenomenon, in which the chemotherapeutic drugs are eliminated from target cells. Consequently, inhibiting P-gp transporter function is a prospective strategy for cancer treatment. In the current study, the SuperDRUG2 database containing >4600 pharmaceutical compounds was virtually screened toward the P-gp transporter utilizing the docking predictions. For inhibitors with a docking score lower than −10.5 kcal/mol, molecular dynamics (MD) simulations were performed, accompanied by binding energy evaluations using the MM-GBSA approach. In accordance with the MM-GBSA//100 ns MD, angiotensin amide (SD003508), terlipressin (SD002603), argipressin (SD002535), and lanreotide (SD001365) exhibited potential binding affinities against the P-gp transporter with ΔGbinding < −120.0 kcal/mol. The outstanding consistency of the investigated inhibitors inside the P-gp binding pocket was shown by the post-dynamics analyses. Additionally, MD simulations of the inhibitor-P-gp complexes in a POPC membrane environment were conducted to mimic the physiological conditions. These results demonstrated that angiotensin amide, terlipressin, argipressin, and lanreotide are promising P-gp inhibitors and deserve additional in-vitro/in-vivo studies.

Link to Full Text
Find this item online

Share

COinS